

A New Building, A New Era

Opening of Weill Greenberg Center heralds the future of patient care

The first newly constructed building in the history of Weill Cornell Medical College, the new 13-story ambulatory care and medical education building at 70th Street and York Avenue, was formally named the Weill Greenberg Center on January 26, reflecting

the continuing philanthropic contributions of two of the college's greatest benefactors, Sanford I. Weill and Maurice Greenberg. The building—in development and construction for the past six years—was opened during a ceremony attended by Weill Cornell Dean Antonio M. Gotto Jr., Cornell University President David Skorton and New York City Mayor Michael Bloomberg, who officially proclaimed January 26 as “Weill Cornell Medical College Day.” Hundreds of donors, faculty, patients and friends of the Medical College attended the event, which included a ceremonial unveiling of a large donor wall and tours of the building's state-of-the-art facilities.

An ebullient Mayor Bloomberg noted that his busy schedule nearly kept him from attending the opening. “Although we have a very busy day, I made it a point to be here to thank Sandy and Hank for making this building a reality,” the mayor said. “They are helping us make New York City a world-class center for medical research and patient care.”

Maurice Greenberg, a member of the Weill Cornell Medical College (WCMC) Board of Overseers, and Sanford >>> page 5



JANET CHARLES

Mr. and Mrs. Robert Appel model the white lab coats for the new Appel Institute for Alzheimer's Research at Weill Cornell. With the Appels are Sanford I. Weill and Dean Antonio M. Gotto Jr.

A 360-Degree View of Alzheimer's

\$15 million gift establishes Appel Institute for Alzheimer's Research


FEW DIAGNOSES ARE MORE MYSTERIOUS AND frightening than that of Alzheimer's disease, which experts say could affect more than 41 million Americans by 2050.

That's why the establishment in December of the new Appel Institute for Alzheimer's Research at Weill Cornell, made possible by a generous \$15 million gift from Helen and Robert Appel, is so vitally important.

The institute's experts, who will come from a variety of disciplines including neurology, neurogenetics, biochemistry and microbiology, will work together to acquire a better >>> page 3

WHAT DO YOU THINK?

To help us keep you up-to-date on breaking research news, *The Scope* has become a monthly publication (excluding July and August). We have also changed the format of the publication to better serve our readers. We welcome your thoughts and encourage you to write to us at scope@med.cornell.edu.



The exterior of the 13-story, 330,000-square-foot Weill Greenberg Center, located at the corner of 70th Street and York Avenue.

Experts Convene to Fight Drug-Resistant TB

Looming threat demands new solutions, researchers say

The bacterium that causes tuberculosis, *Mycobacterium tuberculosis*, infects about nine million people worldwide each year. Although it sickens only about 10 percent of those it infects, nearly one-third of the world's population have already been infected and over 2 million die from the disease annually. And yet the drugs most often used to fight the disease were developed half a century ago, and the diagnostic test for the disease—often unreliable—is over 100 years old.

Given that TB is most lethal in poorer populations already weakened by HIV/AIDS, the situation is getting worse, not better.

of developing treatments, including fast-tracking clinical trials of promising anti-TB compounds as well as funding strategies for research and development initiatives.”

The event, organized by the international medical humanitarian group Doctors Without Borders/Médecins Sans Frontières, brought together more than 100 participants from a wide range of governmental agencies, including the World Health Organization, the U.S. National Institutes of Health, the U.S. Food and Drug Administration and the U.S. Centers for Disease Control and Prevention, as well as representatives of numerous nonprofit foundations, academic institutions and pharmaceutical companies.

One Weill Cornell scientist who spoke at the conference has long advocated a more aggressive approach to TB and the widespread threat of drug-resistant infectious diseases in general.

“With the marked decrease in the number of new antibiotics entering clinical practice, the danger of microbial resistance is growing larger with each passing year,” warned Dr. Carl Nathan, the R.A. Rees Pritchett Professor and chairman of the Department of Microbiology and Immunology. “To cope with infectious diseases like tuberculosis, there needs to be a convergence of innovation, incentive and access,” Dr. Nathan said.

Experts who spoke at the meeting said that the development of new diagnostic tools that can be used easily in developing countries should be a top priority, as well as drugs that require a shorter treatment time and, ideally, an effective TB vaccine. But all of this will take a commitment in effort, money and time.

“Controlling tuberculosis is going to require teamwork,” Dr. Nathan said. “We need global leadership to coordinate government and philanthropic funding, research by the academic, biotechnology and pharmaceutical sectors, and clinical trials.” ■



ISTOCK.COM

That message—and the urgent need for progress against the illness—were the themes of a symposium held Jan. 11 and 12 at the Cornell Club, titled “No Time to Wait: Overcoming Gaps in TB Drug Development.”

“Every year, we see an additional 450,000 new cases of multidrug-resistant TB—including people diagnosed with particularly lethal new resistant strains,” said Howard P. Milstein, a member of the Weill Cornell Board of Overseers and a co-sponsor with Weill Cornell of the symposium. “We must urgently find new ways

the Scope Weill Cornell

THE STEPHEN AND SUZANNE WEISS DEAN, WEILL CORNELL MEDICAL COLLEGE
Dr. Antonio M. Gotto Jr.

DEAN, WEILL CORNELL GRADUATE SCHOOL OF MEDICAL SCIENCES
Dr. David P. Hajjar

VICE PROVOST FOR PUBLIC AFFAIRS
Myrna Manners

DIRECTOR OF COMMUNICATIONS
Jonathan Weil

DIRECTOR OF PUBLICATIONS/EDITOR
Michael Sellers

SCIENCE WRITER
Ernie Mundell

FEATURE WRITER
Gabriel Miller

EDITORIAL ASSISTANT/COPY EDITOR
Andria Lam

DESIGN
Shostak Studios, NYC

PRINCIPAL PHOTOGRAPHY
Amelia Panico

The Scope is a publication of Weill Cornell Medical College and Weill Cornell Graduate School of Medical Sciences. It is published monthly (except for July and August) by the Office of Public Affairs, 525 East 68th Street, Box 144, New York, NY 10021; (212) 821-0560. publicaffairs@med.cornell.edu



For PDF copies of *The Scope* and other Weill Cornell publications, please visit our Web site at www.med.cornell.edu/publications.

A New World of Health

Cornell launches Global Health Research and Training Program

From bird flu to AIDS to global warming, issues that impact human health in one part of the world now have the potential to affect us all.

Recognizing and meeting that challenge is the core of Cornell's new Global Health Program, a collaboration between the university's Ithaca and New York City campuses that is already enrolling its first students.

Comprised of undergraduate, professional and graduate programs, the multidisciplinary effort is being developed by the Medical College and the Cornell colleges of Human Ecology, Arts and Sciences, Veterinary Medicine and Agriculture and Life Sciences. As its first priority, the university is offering stu-

dents an undergraduate minor with an expanded curriculum focusing on global health.

The goal: research into and education in the social, political, economic, environmental and biological factors that drive health problems worldwide. That interdisciplinary networking of expertise and ideas is key to tackling the planet's most daunting health issues, explained Dr. Warren Johnson Jr., the program's co-director.

Funded by the university and the National Institutes of Health, the program “is all about students working together in unique, innovative collaborations that mesh medicine, nutrition, health policy and other elements to bring about fresh approaches to these issues,” said

Dr. Johnson, the B.H. Kean Professor of Tropical Medicine. “We all know that globalization is making the world smaller, and that's especially



Surrounded by Tanzanian families are (from left) Anna Jackson, fourth-year Weill Cornell student; Jaqueline Kung'u, Ph.D. candidate in Cornell's College of Human Ecology, Nutritional Sciences; and Sabra Said Khalfan (far right), a graduate of Cornell's College of Human Ecology, Nutritional Sciences.

true for issues of human health,” said program co-director Dr. Rebecca Stoltzfus, professor of nutritional science at Cornell. “We believe that this unique initiative can and will address health concerns that go beyond national borders—issues that disproportionately affect the resource-poor and call for multidisciplinary solutions.” ■

>>> from page 1

A 360-Degree View of Alzheimer's

understanding of Alzheimer's disease and other neurodegenerative illnesses.

“Helen and I have witnessed the devastating effects of Alzheimer's firsthand. It is our sincere hope that this institute will provide the resources necessary to help increase understanding of the disease,” said Mr. Appel, a member of the Board of Overseers of the Medical College and chairman of the recently announced \$1.3 billion “Discoveries That Make a Difference” capital campaign for Weill Cornell.

The creation of the new Institute means that “Weill Cornell will continue to be a leader in the quest for a greater knowledge of this disease,” said Dr. Antonio M. Gotto Jr., dean of the Medical College.

That leadership is already making tangible progress in the fight against Alzheimer's. For example, a team led by Weill Cornell Associate Professor of Clinical Neurology Dr. Norman Relkin recently identified a panel of 23 protein biomarkers in cerebrospinal fluid that act as a kind of neurochemical “fingerprint” for the disease.

“Right now, doctors have no means of definitively spotting Alzheimer's in patients,” explained Dr. Relkin, who is also director of the Memory Disorders Program at NewYork-Presbyterian/Weill Cornell Medical Center. “We're excited that the new biomarker panel could lead us to the first-ever reliable diagnostic test for the disease.” His team published the findings in the Dec. 12 *Annals of Neurology*.

“Alzheimer's is a growing epidemic that demands the level of attention that the institute will provide,” said Dr. Flint Beal, chairman of the Department of Neurology and Neuroscience at Weill Cornell, and neurologist-in-chief at NewYork-Presbyterian/Weill Cornell. “But right now, scientists don't even fully understand what causes Alzheimer's disease,” he said. “Resources like the Appel Institute are absolutely essential in order for medical science to close the existing research gap.”

“Instead of just following existing clinical protocols, these diverse research collaborations will offer a 360-degree view of Alzheimer's,” said Dr. David Hajjar, vice provost and dean of the Weill Cornell Graduate School of Medical Sciences. “I'm optimistic we will expose the cause of Alzheimer's and eventually, its cure,” he said. ■

Student-Led Forum Opens Dialogue on Neglected Third-World Diseases



RICHARD LOBELLE

Sandeep Kishore, one of the organizers of the Jan. 30 forum on neglected diseases in developing countries.

FOR WEILL CORNELL SECOND-

year MD-PhD student Sandeep Kishore, the Tri-Institutional Forum on Neglected Diseases was a long time in coming.

When he was a high school junior in Radford, Va., Kishore traveled with a small group on a tour of India led by his grandfather's best friend. It was a transformative experience for Kishore: he connected very deeply to his parents' native culture, to India, and to his grandfather's best friend, whose humility and philosophy embodied the Hindu dharma. Kishore's pilgrimage would have other, decidedly different lasting effects, though; when his grandfather's best friend died from cerebral malaria, Kishore decided to dedicate himself to the study of global health.

Fast forward eight years to last November, when Weill Cornell Dean Antonio M. Gotto Jr. issued a call to faculty and students to

find new ways to support sub-Saharan African development as part of Cornell University's Africa Initiative. Working with Weill Cornell faculty and students, as well as Christin Price from the national organization Universities Allied for Essential Medicines, Kishore began talking to groups that might want to organize a forum on neglected diseases.

"We were floored by the response from the community," Kishore said. "What began as a tiny forum grew exponentially."

On Jan. 30 in Weill Cornell's Uris Auditorium, Kishore and Price's "tiny forum" included some of the most important names in global health: Dr. Peter Hotez, a Tri-Institutional MD-PhD alumnus and director of the Global Network for Neglected Tropical Disease Control; Dr. Harold Varmus, a Nobel Laureate in Medicine and the president of Memorial Sloan-Kettering Cancer Center; and Dr. Joanna Rubinstein,

former director of Global Health Initiatives at the UN Millennium Project and current director of Strategic Initiatives at the Earth Institute at Columbia University. Among the Weill Cornell experts were Dr. Warren Johnson, chief of the Division of International Medicine and Infectious Diseases; Dr. Carl Nathan, chairman of the Department of Microbiology and Immunology; Dean Gotto; and others from the Tri-Institutional and New York City global health community.

During the forum, invited speakers introduced and defined neglected diseases and discussed current conditions throughout the Third World.

The neglected diseases are commonly defined as a core group of 13 tropical, parasitic and bacterial infections that predominantly affect the developing regions of sub-Saharan Africa, Asia and the Americas. Many diseases, and specifically helminthic infec-

tions in which parasites live inside the host, can be effectively and inexpensively treated with available drugs; nevertheless, at least one billion people— one sixth of the world's population—suffer from one or more neglected tropical diseases, according to the World Health Organization.

Beyond defining these diseases, the forum also introduced students to faculty and global health leaders to work on future initiatives.

"The interest has always been here, we're just hoping to centralize and harness it. And we're very proud to have a medical college that is taking on this issue," Kishore said.

The issue of global health has taken root throughout the Medical College, from new groups of just a few students interested in the problem to diverse, large-scale collaborations between Ithaca and New York City.



RICHARD LOBELLE

From left: Sandeep Kishore, Tri-Institutional MD-PhD candidate and forum organizer; Christin Price of the Universities Allied for Essential Medicines; Dr. Carl Nathan, chairman of the Department of Microbiology and Immunology; Lakshmi Sonbuchner; Dr. Sonia Sachs of the Earth Institute at Columbia; Ellis Rubinstein, president of the New York Academy of Sciences; Dr. Joanna Rubinstein; Dr. Peter Hotez; and Dr. Warren Johnson.



RICHARD LOBELLE

Dr. Harold Varmus, Nobel laureate and president of Memorial Sloan-Kettering Cancer Center, was one of several speakers at the forum.

"There is a whole generation that has been inspired to undertake this endeavor in global public health," said Dean Gotto. Currently 40 percent of Weill Cornell students take international electives abroad in dozens of countries, the majority of which are in the developing and Third World where students can have a significant impact on local health care.

Speaking to students about Weill Cornell programs and affiliations in the developing world, Dr. Johnson said, "You as students and graduates can get involved and make a difference. It doesn't happen instantly, but over years you can see the impact that some of the people in this auditorium have made."

A common refrain heard throughout the forum is that universities, and particularly the Tri-Institutional partners and Cornell University in Ithaca, are uniquely positioned to lead the fight against Third World disease by virtue of their specialized knowledge spread across many areas. For Kishore and others who are still in school, there are also vast social resources to be mined.

"There's a lot of power between these institutions and if we combine forces, we could be a world leader," Kishore said. "This forum isn't the end—it's a kickoff point." ■

>>> from page 1

A New Building, A New Era

I. Weill, chairman of the board, both of whom donated a combined \$150 million to WCMC's "Advancing the Clinical Mission" capital campaign, stood proudly in the lobby of the building, which is the centerpiece of the hugely successful campaign. With additional gifts, the building was financed entirely by philanthropy.

"Thanks to the generosity of our donors and friends, we are ushering in a new era of patient care as we open the doors to this unparalleled

elegant, inviting and unexpectedly refined.

More than anything, the building is a pantheon of patient-centered care, and each detail is custom-designed to enhance patients' experiences.

For example, to deal with Manhattan's notorious parking problems, patients can drive their cars into the 70th Street entrance and have them valet-parked in the building's underground garage. As patients ascend the escalator on their way to the Myra Mahon Patient Resource Center on the second floor, they glide past a 58-foot waterfall and a specially commis-

sioned hanging sculpture made of more than 10,000 crystal cubes. The spa-like environment is dotted with peaceful reflective pools and still-water images to promote healing and a sense of well-being. In the early morning hours when the building is quiet, sounds of moving water can be heard echoing throughout. A Best of 2006 Award of Merit for health-care centers and hospitals by New York Construction magazine cited the building's "elegant, innovative" design.

"As a cardiologist and a cardiac researcher, I've spent most of my life in medical facilities, and I can tell you that interactions in a center like this create a higher level of professional patient care and a high level of personal growth," said President Skorton. "People are changed forever through their work in a center like this."

In addition to clinical care and research facilities, the Weill Greenberg Center also will house the Clinical Skills Center, providing students with a state-of-the-art facility to practice clinical skills on standardized "actor" patients.

"Before this, we practiced diagnosing patients in a regular exam room, and the actor patients reported back to the doctors. In the new center, doctors will be able to observe us as we work, which is an amazing learning opportunity," said Ankit Patel, a WCMC medical student and a student member of the Board of Overseers.

"We've dedicated a lot of buildings, but I have a real sense that we're witnessing history for Cornell University," said Dr. Skorton. "This building will be a flagship—people throughout the region will come here for medical care and our students will carry their medical skills to every region of the globe." ■



RICHARD LOBELLE

Sanford I. Weill (left), chairman of the Board of Overseers for Weill Cornell Medical College, greets Maurice Greenberg, a member of the Medical College's Board of Overseers, at the dedication of the Weill Greenberg Center on January 26.

facility," said Dean Gotto. "Many generous and creative people have had a hand in the construction of this facility, but Sandy Weill and Hank Greenberg are the true architects. Their generosity and vision built this incredible building."

The 330,000-square-foot building was designed by Polshek Partnership, New York City. The building's health-care floors were designed in a partnership with Ballinger of Philadelphia. In a happy coincidence, Polshek Partnership's three design partners—Todd H. Schliemann, Susan T. Rodriguez and Richard M. Olcott—are all Cornell University graduates. The building's gently sloped vertical surfaces are made of a specially designed fritted exterior glass that allows soft light to permeate the interior, yet preserves patient privacy. The luminous surface reflects the gothic motif of the original Medical College edifice across York Avenue, while also suggesting a new direction in health care that is



ISTOCK.COM

WCMC Team Spots “Missing Link” for Spinal Cord Repair

FLOODING NERVE CELLS WITH A NATURAL ENZYME CALLED “sAC”

spurred the cells to shoot out new branches and make new neural connections, WCMC researchers reported in a recent issue of *Nature Neuroscience*. “Identifying the role of sAC has been like finding a crucial ‘missing link’ in the biochemical chain that leads to nerve cell regeneration,” explained lead author Dr. Samie Jaffrey, associate professor of pharmacology. He and graduate student co-researcher Karen Wu say the finding moves us one step closer to the therapeutic regrowth of damaged spinal cords. “Trials using a gene therapy approach to do just that are on the horizon,” Dr. Jaffrey said. ■

A Better Pharmacologic Way to Get Your ZZZs


EASY, UNINTERRUPTED SLEEP, A GOOD BALANCE BETWEEN REM AND

non-REM slumber, and that refreshed, non-drowsy feeling the next day: one experimental sleep aid under development might offer it all, Weill Cornell researchers say. “Unlike currently available sleep aids, this compound, gaboxadol, works like a ‘dimmer switch’ in the brain, easing us in and out of slumber in a way that mimics natural sleep,” said co-researcher Dr. Neil Harrison, professor of pharmacology and anesthesiology. Reporting recently in the *Proceedings of the National Academy of Sciences*, his group found that gaboxadol—currently in phase-3 trials—tweaks a very specific brain chemistry to induce and regulate sleep. ■

Two Treatments Beat One for Male OAB

FOUR OUT OF FIVE OLDER MEN WHO TOOK A COM-

bination of two available drugs for overactive bladder (OAB) gained control over the troublesome condition, according to a Weill Cornell-led clinical trial that could set the new standard of care for OAB. “We found that daily use of tolterodine (Detrol LA) and tamsulosin (Flomax), taken together, worked much better than either drug alone in this 12-week study,” said lead author Dr. Steven A. Kaplan, professor of urology at Weill Cornell. In contrast, men who used one drug alone were no better off than those who took a placebo. The trial was published in a recent issue of the *Journal of the American Medical Association*. ■




Dr. Steven A. Kaplan

Lifetime Cost of HIV Care Tops \$618,000

A WEILL CORNELL STUDY CALCULATES THE AVERAGE

cost of treating an HIV-infected American over a lifetime at \$618,900. “About 70 percent of that cost is linked to anti-retroviral and other drugs, which have kept a lot of patients out of more expensive hospital care,” said lead author Dr. Bruce Schackman, chief of the Division of Health Policy in the Department of Public Health. As reported in *Medical Care*, Dr. Schackman’s group used complex computer modeling to assess the cost of caring for a person with HIV over an average post-infection life expectancy of 24.2 years. “The good news is that preventing each infection saves us on average \$303,000 in treatment costs,” Dr. Schackman said. ■



From left: Dr. Leonardo Pignataro, Dr. Neil Harrison and Dr. Fan Jia

New Clinical Scholars



The Friedman Family Foundation Clinical Scholar in Newborn Medicine

DR. LISA EILAND has been named the Friedman Family Foundation Clinical Scholar in Newborn Medicine, an award that will support Dr. Eiland’s research on the impact of stress on the developing brain.

“A premature infant in the intensive care environment is subjected to constant stress including constant lighting, high noise level, and frequent disruptions by health-care providers,” Dr. Eiland said. “Follow-up studies of very low birth-weight infants indicate significant cognitive deficits, in particular affecting learning and memory, in up to 40 percent of cases.”

“Our family is delighted to be able to provide this new Clinical Scholar Award to support the work of an outstanding junior faculty member in this premier neonatology research program,” said Barbara Friedman, a member of the Weill Cornell Board of Overseers and longtime supporter of pediatric research done at Weill Cornell.



The James P. Smith, M.D. Clinical Scholar

DR. BEN-GARY HARVEY, associate professor of clinical medicine, has been named the James P. Smith, M.D. Clinical Scholar. The award will fund research on the patterns of gene expression in the epithelial cells of the small lung airways of individuals with chronic obstructive pulmonary disease (COPD).

The award was established by the Starr Foundation in 2004 to support outstanding faculty in the field of cardiopulmonary medicine. The gift was made in honor of Dr. James P. Smith, who was clinical professor of medicine in pulmonary/critical care medicine.



The Leonard and Fleur Harlan Clinical Scholar

A gift of \$1 million from Leonard and Fleur Harlan has established the Leonard and Fleur Harlan Clinical Scholar Award.

DR. ROGER HARTL, director of the spine program and assistant professor of neurological surgery, has been named its first recipient.

“I am incredibly grateful for this award, which will enable me to devote more time to my research in spine surgery and brain trauma—specifically pursuing research on outcomes analysis in

the treatment of complex spinal disorders,” said Dr. Hartl.

Dr. Hartl joined Weill Cornell in 2004. In addition to his surgical practice, Dr. Hartl has published more than 40 articles—most recently focused on his two current areas of interest, spine surgery and brain trauma.



The Sanford B. Ehrenkranz Family Clinical Scholar in Women’s Health

Associate Professor of Clinical Medicine **DR. ERICA JONES** has been named the Sanford B. Ehrenkranz Family Clinical Scholar in Women’s Health. The award will support Dr. Jones’ research in cardiovascular care for women.

Dr. Jones graduated from Northwestern University in 1987 and received her M.D. from New York Medical College in 1992. She completed her internship, residency and fellowship in cardiology at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. Dr. Jones joined the Medical College faculty as assistant professor of medicine in 1998 and was promoted to associate professor in 2004.

A senior partner of Ehrenkranz & Ehrenkranz LLP, Sanford B. Ehrenkranz has been a supporter of Weill Cornell since 1981. In 1982, he founded Departmental Associates, an organization for lay people interested in supporting and following developments in medical research at Weill Cornell Medical College. He has been a member of the Board of Overseers since 1985.

New Executive Vice Dean Appointed



JOANNE BLAUER has been named to the position of executive vice dean for special projects. She previously served as associate dean and secretary of Weill Cornell Medical College.

“I have asked Ms. Blauer to take this position in order that I may take advantage of her extensive knowledge of academic administration and her more than 25 years of experience here

at Weill Cornell,” said Dr. Antonio M. Gotto Jr., dean of the Medical College. In her new role, Ms. Blauer will work with the dean on initiatives involving Weill Cornell’s ongoing strategic planning efforts. She will continue to serve as one of the dean’s senior advisers.

The functions of the secretary of the Medical College will move to the Office of University Counsel, making the Medical College’s structure consistent with the Ithaca model. The Office of Faculty Affairs will continue to report to Executive Vice Dean Dr. David Hajjar. ■

Dr. Donald D'Amico Appointed Chairman of Ophthalmology

DR. DONALD D'AMICO HAS BEEN APPOINTED



chairman of the Department of Ophthalmology at Weill Cornell Medical College and ophthalmologist-in-chief at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. An internationally recognized leader in treatment of diabetes-related eye disease, Dr. D'Amico's major interests include vitreoretinal surgery;

diabetic retinopathy; experimental lasers and other technologies for the surgical treatment of vitreoretinal disorders such as retinal detachment; macular degeneration; and endophthalmitis and intravitreal drug therapy.

"Dr. D'Amico is an award-winning teacher and outstanding researcher, and we are delighted that he will be bringing his formidable skills to the Department of Ophthalmology at Weill Cornell Medical College," said Dr. Antonio M. Gotto Jr., dean of the Medical College.

Dr. D'Amico most recently served as professor of ophthalmology at Harvard Medical School and associate chief of ophthalmology and director of the Diabetic Unit at the Massachusetts Eye and Ear Infirmary.

As a distinguished national and international lecturer, Dr. D'Amico has been the recipient of many honors, including the Honor Award and the Senior Achievement Award from the American Academy of Ophthalmology.

A graduate of the University of Illinois College of Medicine, Dr. D'Amico completed his residency at the Massachusetts Eye and Ear Infirmary. He completed his fellowship in vitreoretinal diseases at the University of Miami, Bascom Palmer Eye Institute, followed by selection as chief resident in ophthalmology at the Massachusetts Eye and Ear Infirmary prior to joining the Harvard faculty. ■



COVER STORY: A New Building, A New Era

The 330,000-square-foot Weill Greenberg Center opens, heralding the future of patient care and medical education.

2 SCIENCE BRIEFS: EXPERTS CONVENE TO FIGHT DRUG-RESISTANT TB

Emphasis is placed on the immediate need to fast-track clinical trials for anti-TB medications.

3 SCIENCE BRIEFS: A NEW WORLD OF HEALTH

Cornell and WCMC launch a new Global Health Research and Training Program.

4 STUDENT NEWS: DIALOGUE ON NEGLECTED THIRD-WORLD DISEASES

How one student's personal experience with malaria led to an international forum at WCMC.

6 SCIENCE AT A GLANCE: A BETTER PHARMACOLOGIC WAY TO GET YOUR ZZZS

Gaboxadol may act as a "dimmer switch" to aid in sleep.

7 ACADEMIC AFFAIRS AND APPOINTMENTS: NEW CLINICAL SCHOLARS

Philanthropy funds several new clinical scholar positions at the Medical College.

COVER STORY: A 360-Degree View of Alzheimer's Disease

Mr. and Mrs. Robert Appel's gift of \$15 million establishes the Appel Institute for Alzheimer's Research.



Weill Cornell Medical College and
 Weill Cornell Graduate School of Medical Sciences
 Office of Public Affairs, Box 144
 1300 York Avenue
 New York, NY 10021

ADDRESS CORRECTION REQUESTED

Non-Profit Org.
 U.S. Postage
 PAID
 New York, NY
 Permit No. 5503